![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
G Tavernier, J Galitzky, A Bousquet-Melou, JL Montastruc and M Berlan
Laboratoire de Pharmacologie Medicale & Clinique, Institut National de la Sante et de la Recherche Medicale, Unite 317, Faculte de Medecine, Toulouse, France.
The presence of a beta-3 adrenoceptor (in addition to the classical beta-1 and beta-2 adrenoceptors) and its involvement in the control of heart rate was investigated in the dog. Experiments were carried out in conscious normal and sinoaortic denervated dogs (i.e. animals deprived of baroreceptor pathways). In normal dogs, infusion of isoproterenol, BRL 37344 (4-[-[(2-hydroxy-(3-chlorophenyl) ethyl)- amino]propyl]phenoxyacetate) (a beta-3 adrenergic agonist) or CGP 12177 (4-[3-t-butylamino-2-hydroxypropoxy]benzimidazol-2- one) (a beta-1 beta- 2 adrenergic antagonist reported to act as an agonist for the beta-3 adrenergic receptor) increased heart rate with an order of potency: BRL 37344 > isoproterenol >> CGP 12177. [125I]Cyanopindolol binding (2-2000 pM) was saturable and Scatchard analysis indicated the presence of an homogenous population of binding sites. KD was 12.8 +/- 18.5 pM and maximum binding was 94.2 +/- 12.5 fmol/mg of protein. Competition binding studies on dog heart membranes using 150 pM [125I] cyanopindolol indicated an order of potency (CGP 12177 > isoproterenol > BRL 37344) different from that observed in cardiovascular studies. Isoproterenol stimulated adenylate cyclase activity in heart membranes from normal dogs, whereas CGP 12177 and BRL 37344 were without any stimulating action. The positive chronotropic effects of isoproterenol, BRL 37344 and CGP 12177 were accompanied with a reduction in arterial blood pressure. In sinoaortic denervated animals, isoproterenol infusion provoked tachycardia and hypotension. BRL 37344 and CGP 12177 were without any significant effect on heart rate but induced a rapid and dramatic hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  A. Hicks, G. P. McCafferty, E. Riedel, N. Aiyar, M. Pullen, C. Evans, T. D. Luce, R. W. Coatney, G. C. Rivera, T. D. Westfall, et al. GW427353 (Solabegron), a Novel, Selective beta3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 202 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Morimoto, H. Hasegawa, H.-J. Cheng, W. C. Little, and C.-P. Cheng Endogenous {beta}3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2425 - H2433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tavernier, G. Toumaniantz, M. Erfanian, M.-F. Heymann, K. Laurent, D. Langin, and C. Gauthier {beta}3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human {beta}3-adrenergic receptor Cardiovasc Res, August 1, 2003; 59(2): 288 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Conrath and T. Opthof {beta}3-Adrenoceptors in the heart Cardiovasc Res, December 1, 2002; 56(3): 353 - 356. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Guimaraes and D. Moura Vascular Adrenoceptors: An Update Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Hom, M. J. Forrest, T. J. Bach, E. Brady, M. R. Candelore, M. A. Cascieri, D. J. Fletcher, M. H. Fisher, S. A. Iliff, R. Mathvink, et al. {beta}3-Adrenoceptor Agonist-Induced Increases in Lipolysis, Metabolic Rate, Facial Flushing, and Reflex Tachycardia in Anesthetized Rhesus Monkeys J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 299 - 307. [Abstract] [Full Text]
|
|
|
|
|
|
M. Murakami, Y. Tomiyama, K. Hayakawa, M. Akahane, Y. Ajisawa, Y.-C. Park, N. Ohnishi, T. Sugiyama, and T. Kurita Effects of beta -Adrenergic Stimulation on the Acutely Obstructed Ureter in Dogs J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 67 - 75. [Abstract] [Full Text]
|
|
|
|
|
|
C. Gauthier, G. Tavernier, J.-N. Trochu, V. Leblais, K. Laurent, D. Langin, D. Escande, and H. Le Marec Interspecies Differences in the Cardiac Negative Inotropic Effects of beta 3-Adrenoceptor Agonists J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 687 - 693. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Sokoloff, R. F. Kirby, and M. S. Blumberg Further evidence that BAT thermogenesis modulates cardiac rate in infant rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 1998; 274(6): R1712 - R1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Cheng, Z.-S. Zhang, K. Onishi, T. Ukai, D. C. Sane, and C.-P. Cheng Upregulation of Functional {beta}3-Adrenergic Receptor in the Failing Canine Myocardium Circ. Res., September 28, 2001; 89(7): 599 - 606. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
